BOLD Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.520

-29.73%

-0.575

-19.01%

-0.595

-15%

Estimates Revision

Stock Price

Go Up

+2.34%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast BOLD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BOLD is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

4.00

Averages

4.00

High

4.00

Current: 0.000

Low

4.00

Averages

4.00

High

4.00

H.C. Wainwright

Buy

downgrade

$5 -> $4

2025-08-11

Reason

H.C. Wainwright

Price Target

$5 -> $4

2025-08-11

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Boundless Bio to $4 from $5 and keeps a Buy rating on the shares following the Q2 report.

Goldman Sachs

Richard Law

initiated

2025-07-24

Reason

Goldman Sachs

Richard Law

Price Target

2025-07-24

initiated

Reason

Goldman Sachs analyst Richard Law initiated coverage of Boundless Bio with an Early-Stage Biotech rating, saying the company's combo approach for its lead asset BBI-355 comes with high risk.

H.C. Wainwright

NULL -> Buy

initiated

2025-06-02

Reason

H.C. Wainwright

Price Target

2025-06-02

initiated

NULL -> Buy

Reason

H.C. Wainwright initiated coverage of Boundless Bio with a Buy rating and $5 price target. Boundless is a clinical-stage biotechnology company developing novel oncology therapeutics, which are directed at addressing extrachromosomal DNA, the analyst tells investors in a research note. The firm says that with a "lengthy" cash runway extending into 2027, the company has "considerable risk-mitigation, and high upside potential at the current levels."

Leerink

Outperform -> Market Perform

downgrade

$15 -> $3

2025-05-27

Reason

Leerink

Price Target

$15 -> $3

2025-05-27

downgrade

Outperform -> Market Perform

Reason

Leerink downgraded Boundless Bio to Market Perform from Outperform with a price target of $3, down from $15. The company is discontinuing current monotherapy and combination arms of BBI-355 in the Phase 1/2 POTENTIATE clinical trial based on a narrow therapeutic index observed with dosing, the analyst tells investors in a research note. The firm is moving to the sidelines pending validation of Boundless Bio's new approach. It removed all value for the CHK1 program until the company validates the BBI-355 and BBI-825 combination hypothesis in specific tumor types.

Valuation Metrics

The current forward P/E ratio for Boundless Bio Inc (BOLD.O) is -0.53, compared to its 5-year average forward P/E of -0.99. For a more detailed relative valuation and DCF analysis to assess Boundless Bio Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-0.99

Current PE

-0.53

Overvalued PE

-0.14

Undervalued PE

-1.83

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.11

Current EV/EBITDA

0.62

Overvalued EV/EBITDA

2.05

Undervalued EV/EBITDA

-2.28

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

BOLD News & Events

Events Timeline

No data

News

9.5

2025-08-05Newsfilter

Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights

5.0

2025-07-31Newsfilter

Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board

1.0

2025-06-05Newsfilter

Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

People Also Watch

Frequently Asked Questions

What is Boundless Bio Inc (BOLD) stock price today?

The current price of BOLD is 1.31 USD — it has increased 0 % in the last trading day.

What is Boundless Bio Inc (BOLD)'s business?

Boundless Bio, Inc. is a clinical-stage oncology company, which is engaged in cancer therapeutics that address the unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. The Company’s lead therapeutic candidate ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in oncogene amplified preclinical cancer models, including those enabled by ecDNA, and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its next program is directed at a previously undrugged kinesin target.

What is the price predicton of BOLD Stock?

What is Boundless Bio Inc (BOLD)'s revenue for the last quarter?

Boundless Bio Inc revenue for the last quarter amounts to -15.15M USD, decreased -19.06 % YoY.

What is Boundless Bio Inc (BOLD)'s earnings per share (EPS) for the last quarter?

Boundless Bio Inc. EPS for the last quarter amounts to -10210000.00 USD, decreased -25.74 % YoY.

What changes have occurred in the market's expectations for Boundless Bio Inc (BOLD)'s fundamentals?

The market is revising No Change the revenue expectations for BOLD for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 2.34%.

How many employees does Boundless Bio Inc (BOLD). have?

Boundless Bio Inc (BOLD) has 64 emplpoyees as of January 10 2026.

What is Boundless Bio Inc (BOLD) market cap?

Today BOLD has the market capitalization of 29.33M USD.